Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer, the First Egyptian Experience

Gareer WY1, Gareer HWY1, Hussein Alaadin1*, Mansour O2, Alghazali H3 and Saber A4

1Surgical Oncology, National Cancer Institute, Cairo University, Egypt
2Medical Oncology Departments, National Cancer Institute, Cairo University, Egypt
3Medical Oncology Department, Ain-Shams University, Egypt
4Medical Oncology Department, Menia University, Egypt

Submission: June 27, 2017; Published: July 14, 2017

*Corresponding author: Hussein Alaadin, Surgical Oncology, National Cancer Institute, Cairo University, Egypt, Email: alaadin.osman@yahoo.com

Abstract

Background: For 3 decades cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been introduced as an effective technique in treating peritoneal carcinomatosis (PC) from different primaries with promising results in selected patients. The aim of this study is to evaluate the early and late outcomes of CRS and HIPEC in management of recurrent epithelial ovarian cancer (REOC) with PC as the first Egyptian experience.

Methods: In the period between September 2009 and December 2013 we treated 42 patients with PC from REOC with CRS and HIPEC using the closed abdominal technique. The perioperative complications, toxicity grade, overall survival (OS), disease free survival (DFS), mortality rates, and effects of peritoneal carcinomatosis index (PCI), completeness of cytoreduction, patient age and tumor type and grade on survival had been reported and analyzed.

Results: The mean age was 51.2±7.9 (range 34-64 years). PCI was <16 in 47.7%; 16-20 in 45.2% and >20 in 7.1%). Postoperative mortality rate was 2.38%. The mean disease free survival (DFS) was 11.9±9.75 (median 9.0; range 0-51 months), while the cumulative overall survival (OS) was 73.6% at 18 months, and 55.5% at 2 years. PCI found to be a significant risk factor when we compared PCI < 16 with PCI > 16 (p = 0.001. Completeness of cytoreduction was associated with higher OS. Age > 60 years was associated with a significantly lower OS (p = 0.003). Serous papillary tumors were associated with better survival. Low tumor grade was associated with longer OS survival with no significant difference (0. 628).

Conclusion: CRS and HIPEC along with the extent of the disease and the extent of cytoreduction play a crucial role in the survival of patients with REOC, and as a technique it is feasible with acceptable morbidity, mortality (2.38%) and toxicity when good patients’ selection and systematic intra operative assessment are strictly applied.

Keywords: Recurrent epithelial Ovarian Cancer; Cytoreductive surgery; Intraperitoneal hyperthermic chemotherapy

Abbreviations: CRS: Cytoreductive Surgery; HIPEC: Hyperthermic Intraperitoneal Chemotherapy; PC: Peritoneal Carcinomatosis; REOC: Recurrent Epithelial Ovarian Cancer; OS: overall survival; DFS: Disease Free Survival; PCI: Peritoneal Carcinomatosis Index; EOC: Epithelial ovarian cancer

Introduction

Epithelial ovarian cancer (EOC) is the most common cause of primary ovarian malignancy accounting for 95% of ovarian neoplasms, with a lifetime risk of 1 in every 70 women [1,2], making it the sixth commonest malignancy in women worldwide, and it is one of the leading causes of cancer related deaths in women with over 100,000 deaths due to the disease each year worldwide [3,4]. It has an indolent clinical course leading to most cases being diagnosed in an advanced stages (FIGO stage III, IV) with about 75% of cases having peritoneal deposits at...
time of diagnosis [5,6], the 5 year survival for such patients is >25% with the standard therapy being maximal cytoreductive surgery followed by platinum-based chemotherapy [7-9] which despite having 70-80% response rate still about 75% of these patients will have recurrent disease mostly confined to the peritoneal cavity with a median disease free survival 18-28 month only [10,11] ultimately suffering from bowel obstruction and death and thus the need for better loco regional control for such advanced stages [12,13].

Another approach which was originally described by Sugar baker in 1980’s combines surgery with HIPEC with surgery aiming at complete removal of tumor burden through peritonectomy and visceral resection to remove all macroscopically identified tumor [14,15] and during the last decade reports with good results are being published from many centers [7,16] and survival improvement is mainly dependent on completeness of cytoreduction thus supporting the key role of radical surgery in REOC treatment [17].

Patients and Methods

Between September 2009 and December 2013, our team treated 42 women who experienced recurrence after initial treatment with cytoreductive surgery and systemic chemotherapy. All cases were submitted to complete labs (blood count, blood chemistry tests, urine analysis and CA125 serum levels), Pelvi-abdominal CT scan and PET-CT scan to exclude extra-abdominal disease and assess disease extension and the chances of optimal cytoreduction. The PCI was calculated by summing the tumor volume in each of the 13 abdomino-pelvic regions defined by Sugar baker [18]. Patients’ inclusion criteria included: women aged between 34 and 68 years with recurrent ovarian cancer; Eastern Cooperative Group Performance Status (ECOG PS) ≤ 2; no evidence of disease outside the abdomen. No ovarian cancer; Eastern Cooperative Group Performance Status (ECOG PS) ≤ 2; no evidence of disease outside the abdomen. No metastasis, and with normal cardiac, hepatic, renal, respiratory and bone marrow functions. The exclusion criteria were as follows: ECOG PS <2; evidence of extra-abdominal metastatic disease, presence of non-respectable liver metastasis, extensive bowel obstruction or peri-portal involvement or any intra-abdominal involvement that will not result in CC-0 or CC-1 cytoreduction. The protocol was approved by the Ethical Committee of the hospital, and an informed consent was signed by all patients.

Surgical Technique

All patients were operated on by the same surgical team and under general anesthesia we started our procedure with proper exploration to properly calculate the PCI and assess operability. Peritonectomy procedure was tailored according to the extent of disease. Affected organs were resected in bloc with affected pelvic peritonum. Surgical procedures done are summarized in (Table 1). Retropertoneal and pelvic lymphadenectomy were performed when affected. The completeness of cytoreduction was assessed according to Sugar baker classification CC-0; no residual disease; CC-1; minimal residual disease < 2.5 mm; CC-2, residual disease of 2.5 mm-2.5 cm; and CC-3, disease > 2.5 cm. At the end of CRS we started the HIPEC using the closed technique using Cisplatin (CDDP 50 mg/m2) + Doxorubicin (15mg/m2) or Cisplatin-Mitomycin C (25mg-3.3 mg/m2/L). The perfusion continued for 90 minutes at an average temperature of 42-43°C. At the end of the procedure, restoration of bowel continuity for any resected bowel is established.

Follow-Up

The patients were followed up every 3 months during the first 2 years after surgery and every 6 months later with physical examination, hematological-biochemical examinations, tumor markers (CEA, CA-125), and pelvi-abdominal CT scan and PET scan for cases with elevated Ca-125 and negative CT scan. The recurrences and the sites of recurrence were recorded (Table 1).

Table 1: Surgical procedures.

| Peritonectomy & Other procedures     | Number of cases | percentage |
|--------------------------------------|-----------------|------------|
| Rt. sub diaphragmatic                | 38              |            |
| Lt. sub diaphragmatic                | 31              |            |
| Completion of greater omentectomy    | 37              |            |
| Lesser omentectomy                   | 1228.6          |            |
| Pelvic peritonectomy                 | 36              | 85.7       |
| Pelvic Peritonectomy + partial cystectomy | 2              | 4.76       |
| Pelvic Peritonectomy + anterior resection of the rectum | 4 9.52          |            |
| Right parietal                       | 32              |            |
| Left parietal                        | 29              |            |
| Cholecystectomy                      | 25              | 59.5       |
| Splenectomy                          | 19              | 45.2       |
| Small bowel resection                | 9               | 21.4       |
| Right colectomy                      | 8               | 19         |
| Subtotal colectomy                   | 5               | 11.9       |
| Pelvic, Para-aortic lymph node resection | 12            | 28.6       |
| Partial gastrectomy                  | 2               | 4.76       |

Statistical Analysis

All data were collected prospectively. Descriptive statistics were generated for all measures, including means, ranges, and standard deviations for continuous measures and frequencies and proportions for categorical data. OS was calculated from the date of surgery to the last known date of follow-up or the date of death. Estimates of survival were calculated by using the Kaplan-Meier (product-limit) method; analysis with Cox proportional hazards was performed on all pertinent clinico-pathologic variables to determine each variable’s association with survival. Group comparisons of OS were performed
by using the approximate v2 statistic for the log-rank test. Additionally, the Cox proportional-hazards regression model was used in a stepwise fashion to perform a multivariate analysis of clinicopathologic factors to determine an overall model of independent predictors of OS. Statistical significance was defined as a P value <.05.

Results

In 42 patients the mean age was 51.2±7.9 (range 34-64 years), PCI was <16 in 47.7%; 16-20 in 45.2% and >20 in 7.1%. The mean operative time was 366±69 min (range 230-510 min); with a blood loss mean of 883±389 cc, (range 280-2100 cc.). Completeness of cytoreduction was: CC-0 in 66.7% and CC-1 in 33.3 % of patients. The mean hospital stay was 12±6 days (range 6-20 days) among which the mean intensive care unit (ICU) stay was 5±2 days (range 1-20 days).

Postoperative morbidity (according to The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTACE) version 4.03 updated in June, 2010) and mortality are presented in (Table 2). The mean disease free survival (DFS) was 11.9±9.75 (median 9.0; range 0-51 months), while the cumulative overall survival (OS) was 73.6% at 18 months, and 55.5% at 2 years (Figure 1). Patient age had an effect on OS with Age > 60 years was associated with a significantly lower OS (p = 0.003), PCI was found to be a significant risk factor when we compared PCI < 16 with PCI > 16 (p = 0.001) (Figure 2), Completeness of cytoreduction (whatever the PCI) was associated with apparently higher OS proportion, but there was no significant difference between CC-0 and CC-1 (p = 0.125) (Figure 3), tumor grade affect OS with no statistical difference (p = 0.225). The Different risk factors in all patients including age, type of pathology, tumor grade, PCI and completeness of cytoreduction and their relation to cumulative survival are presented in (Table 3).

Table 2: Postoperative morbidity and mortality.

| Complication                  | Number | Percentage |
|-------------------------------|--------|------------|
| Prolonged ileus               | 21.42  | 9          |
| Nausea                        | 9      | 21.42      |
| Urinary tract infection       | 49.52  |            |
| Pleural effusion              | 5      |            |
| Wound infection               | 6      | 14.2       |
| Neutropenia grade II          | 4      | 9.52       |
| Pneumonitis                   | 3      | 7.14       |
| Renal impairment              | 2      | 4.76       |
| Enterocutaneous fistulas      | 2      | 4.76       |
| Bleeding                      | 2      | 4.76       |
| GI fistulas                   | 1      | 2.38       |
| Mortality                     | 12.38  |            |

Table 3: Risk factors and their relation to cumulative survival.

| Factor                          | n  | Cumulative Survival (%) | p value |
|---------------------------------|----|-------------------------|---------|
| Age                             |    |                         |         |
| > 60 yrs.                       | 24 | 32.5%                   |         |
| ≤ 60 yrs.                       | 18 | 84.6%                   |         |
| Pathology                       |    |                         |         |
| Serous                          | 22 | 76.2%                   | 0.02    |
| Non-serous (Mucinous)           | 16 | 35.4%                   |         |
| Undifferentiated                | 4  | 0%                      |         |
| Grade                           |    |                         |         |
Discussion

EOC has an indolent course and more than 60% of cases are diagnosed in advanced stages and also it tends characteristically to disseminate intraperitoneally. Most of these cases experience recurrence in first 3 years after diagnosis and treatment thus the need for better local control [19]. CRS and HIPEC has been implemented as a treatment for EOC with peritoneal deposits and have shown to be efficient when applied either as (interval HIPEC) meaning after neoadjuvant chemotherapy without previous surgery or as (consolidation HIPEC) after initial CRS and a full course of adjuvant chemotherapy in patients with a clinically complete response [20].

The importance of HIPEC in treatment of REOC was proved in a recent randomized trial by J Spiliotis et al. [19] where the patients were classified into 2 groups, the first group was treated with CRS and HIPEC followed by chemotherapy and the second group were only treated by CRS and chemotherapy. They reported a significant difference in survival, as they found CC0 in HIPEC limb survival 30.9 month compared to 16.1 month in CC0 without HIPEC thus highlighting the beneficial effect of HIPEC.
over CRS only [19]. Another work by Pedro Antonio et al. also measured disease free survival after 1 and 2 years and it was 81% and 67% with HIPEC and only 66% and 33% in CRS without HIPEC [21], this confirms the importance of HIPEC after CRS and in our work comparative results were found as we had an overall survival of 73.6% at 18 month and 55.5% at 2 years with a mean DFS 11.9±9.75 month.

The extent of cytoreduction is one of the most important prognostic factors, and it improves greatly OS whatever the disease stage if complete cytoreduction (CC-0 or CC-1) is followed by HIPEC [22]. In our study the completeness of cytoreduction had a great effect on the cumulative survival which was 74.7% and 35.7% with CC0 and CC1 respectively, this was also supported by various studies as Ingmar konigsvainer et al. [23] who stated in his study which included 90 patients that those who had CC0-1 had better overall survival than those who had CC2-3 cytoreduction, also Rene Warschkow et al. [24] published similar results and among their 52 patients those who had CC0 their survival was 71% at 2 years and 63% at 5 years and these numbers decreased with CC1-2 patients(39 patient) to 36.7% and 17%, and further decreased with CC2 patients (20 patient) to 17.5% and 0 % at 2 years and 5 years respectively [24], also Spliotis et al. [19] results confirmed the importance of complete cytoreduction with CC0 , CC1, CC2 having survival of 30.9, 23.9 and 12.1 month respectively.

Mulier S et al. [25] published their results on recurrent EOC patient series, and their median OS and median disease-free survival after CRS and HIPEC followed by adjuvant chemotherapy were 15-57 months and 3-48 months, respectively, while 5-year OS and 5-year disease-free survival were 18-57 % and 0-12.5 % respectively When a complete cytoreduction was achieved, median OS was 97.4 months and 5-year OS was 63–67 %.

The extent of cytoreduction is one of the most important prognostic factors, and it improves greatly OS whatever the disease stage if complete cytoreduction (CC-0 or CC-1) is followed by HIPEC [22]. In our study the completeness of cytoreduction had a great effect on the cumulative survival which was 74.7% and 35.7% with CC0 and CC1 respectively, this was also supported by various studies as Ingmar konigsvainer et al. [23] who stated in his study which included 90 patients that those who had CC0-1 had better overall survival than those who had CC2-3 cytoreduction, also Rene Warschkow et al. [24] published similar results and among their 52 patients those who had CC0 their survival was 71% at 2 years and 63% at 5 years and these numbers decreased with CC1-2 patients(39 patient) to 36.7% and 17%, and further decreased with CC2 patients (20 patient) to 17.5% and 0 % at 2 years and 5 years respectively [24], also Spliotis et al. [19] results confirmed the importance of complete cytoreduction with CC0 , CC1, CC2 having survival of 30.9, 23.9 and 12.1 month respectively.

PCI is an important independent factor in determining survival and in our work we compared PCI> 16 and PCI < 16 with the overall survival being 86.1% and 15.8% respectively, a result that was supported by Spliotis et al. [19] whose results showed that cases with PCI > 15 had better survival of 30.4 month versus 21.5 month in cases with PCI<15, even in their Non HIPEC limb of the study it was 15.4month versus 9.2 month respectively for same PCI groups [19], in another study they stated that PCI does not affect survival so long as complete cytoreduction could be achieved, in another words the effect of high PCI is a result of higher incidence of inability to reach CCO [23].

A recent review stated that the morbidity and mortality associated with HIPEC which was the main concern, has declined over the years and is now comparable to that of CRS alone, and they reviewed various studies with acceptable morbidity and mortality rates, with the Major complications being anastomotic leakage, bowel perforation, and intraperitoneal hemorrhage and wound dehiscence [27]. In our study the rate of complications was comparable with prolonged ileus and nausea being the most common and happened in 21.42% of patients, wound infection in 14.2%, leakage with peritonitis in only 2 patients (4.76%) and mortality in only 1 of our 42 patients (2.38%).

**Conclusion**

Cytoreductive surgery and HIPEC for ovarian tumors with peritoneal metastasis is feasible with acceptable morbidity and mortality when good patients’ selection and systematic intra operative assessment are strictly applied. And it offers a significant survival benefit over cytoreductive surgery alone especially when complete cytoreduction CC0 could be achieved.

**Conflict of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.

**References**

1. Surveillance (2014) Epidemiology, and End Results (SEER). National Cancer Institute, USA.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1): 11-30.
3. Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics. CA Cancer J Clin 55(2): 74-108.
4. Bristow R (2007) Primary Cytoreductive Surgery for Advanced Stage Ovarian Cancer: indications for Radical Resection. Cancerologia 1: 31-36.
5. Slomovitz B, Soliman P, Wolf J (2006) Gynecologic Cancers. The MD Anderson surgical oncology handbook, (4th edn), Lippincott Williams and Wilkins, Philadelphia, USA.
6. Sehouli J, Senyuva F, Fotopoulos C (1999) Neumann U Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer J Surg Oncol 99(7): 424-427.
7. Di GA, Naticchioni E, Bucchi D (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2): 315-25.
8. Bookman MA, McGuire WP, Kilpatrick D (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14(6): 1895-902.
9. Deraco M, Rossi CR, Pennacchioli E (2001) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87: 120-126.
10. Bakrin N, Classe JM, Pomel C, Gouys (2014) Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 151(3): 347-353.
11. Bae JH, Lee JM, Ryu KS (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106(1): 193-200.
12. Armstrong DK (2002) Relapsed ovarian cancer: challenges and
management strategies for a chronic disease. Oncologist 7: 20-28.
13. Gori J, Castano R, Toziano (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer: Int J Gynecol Cancer 15(2): 233-239.
14. Sugarbaker PH (1996) Peritoneectomy procedures. Cancer Treat Res 221(1): 235-253.
15. Mohamed F, Cecil T, Moran B, Sugarbaker P (2011) A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 18(2): 84-96.
16. Pomel C, Ferron G, Lorimier G (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicenter trial. CHIPOWAC study. Eur J Surg Oncol 36(6): 589-593.
17. Hahmann M, Lueck HJ, Peelcher M, Wimberger P (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the desktopi trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16(5): 1324-1330.
18. Sugarbaker PH (1999) Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Archives of Surgery 364(6): 576-587.
19. Spiliotis E, Halkia E, Lianos N Cytoreductive (2015) Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study Ann Surg Oncol 22(5): 1570-1575.
20. Helm CW, Richard SD, Pan J, Bartlett D (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20(1): 61-69.
21. Pedro Antonio, Cascades-Campos J (2014) Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer. Ann Surg Oncol 21(7): 2383-2389.
22. Schorge JO, Garrett LA, Goodman A (2011) Cytoreductive surgery for advanced ovarian cancer: quo vadis Oncology 25(10): 928-934.
23. Ingmar Königsmann, Philipp Horvath (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single center experience Langenbecks Arch Surg 399(5): 589-594.
24. Rene Warschikow, Ignazio (2012) Tarantino Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients Patient Safety in Surgery p. 6-12.
25. Muller S, Claus JP, Dierieck V (2012) Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 18(25): 3793-803.
26. Halkia E, Spiliotis J, Sugarbaker P (2012) Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract 5: 341-842.
27. Aditi Bhatt, Olivier Glehen (2016) The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. Indian J Surg Oncol 7(2): 188-197.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php